Antiverse · $9.3M · Series A

UK-based biotech company Antiverse has closed a $9.3 million Series A round. The company uses AI to design therapeutic antibodies for hard-to-target disease targets. The round was led by Soulmates Ventures.

AI-generated: summaries written by AI from the linked sources. How we use AI